OHSU

IRB #

IRB00009421

Title

A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Principal Investigator

Emma Scott

Study Purpose

To evalute the safety and tolerability and determine the maximum tolerated dose of Cafilzomib in patients with relapsed amyloidosis.

Medical Condition(s)

Relapsed Amyloidosis

Eligibility Criteria

-Males and females ≥ 18 years of age
-Objective, measureable, symptomatic organ involvement
-Relapsed (progressed after prior response) or refractory
(failed to achieve at least a partial response) to at least one
prior therapy for amyloidosis

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

approx 4 years

Minors Included

No

Contact

Amy Bedford
#503-494-6171
bedforda@ohsu.edu

Sponsor

Onyx Pharmaceuticals

Recruitment End

02/14/2020

Compensation Provided

No


Go Back